Arcus Biosciences (NYSE:RCUS) FY Conference September 10, 2025 08:30 AM ET Company ParticipantsRichard Markus - CMOJennifer Jarrett - COOConference Call ParticipantsTerrence Flynn - U.S. Biopharma AnalystTerrence FlynnGreat. Good morning. Thanks for joining us, everybody. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. I'm very pleased to be hosting Arcus this morning. Joining us from the company, we have Jennifer Jarrett, the company's Chief Operating Officer, and Richard Markus, the company's ...

Summary of Compugen (CGEN) FY Conference Call - September 05, 2025 Company Overview - **Company**: Compugen Ltd. - **Industry**: Clinical-stage immunotherapy, specifically immuno-oncology - **Focus**: Utilizes AI/ML-driven predictive tools for discovering novel drug targets - **Key Collaborations**: Partnerships with AstraZeneca and Gilead [1][3] Core Points and Arguments Development Strategy - Compugen has a rich pipeline with two fully owned clinical assets: COM701 (PVRIG antibody) and COM902 (anti-TIGIT antibody) [3][4] - COM902 is licensed to AstraZeneca for use in a bispecific molecule, relvegostomig, currently in Phase III trials [4] - Gilead is developing GS0321, a potential first-in-class antibody identified through Compugen's Unigen™ platform, now in Phase I study [4][24] Computational Platform - Unigen™ - Unigen™ focuses on target discovery in oncology, identifying novel drug targets to enhance clinical testing options [5] - The platform has been validated through successful transitions from computational predictions to clinical testing [5] COM701 and Ovarian Cancer - COM701 targets PVRIG, which is highly expressed in ovarian cancer, particularly in less inflamed tumor types [6][7] - The MAIA ovarian cancer study aims to evaluate COM701 as a maintenance treatment for platinum-sensitive patients, with a focus on improving progression-free survival [8][14] - Current standard of care for these patients is limited, creating an unmet need that COM701 could address [10][12] Clinical Trial Design - The MAIA study is randomized and blinded, comparing COM701 monotherapy to placebo [14] - Interim analysis expected in H2 2026, with a goal to show improvement in progression-free survival by more than three months [15] TIGIT Development Landscape - Compugen and AstraZeneca continue to evaluate relvegostomig despite challenges faced by other companies in the TIGIT space [20][21] - The unique characteristics of their TIGIT antibody class, which does not bind FC receptors, may contribute to a favorable safety profile [21][22] Financials and Future Outlook - Compugen reported approximately $94 million in cash as of June, providing a runway into 2027 without relying on royalties or milestones from collaborations [31] - Upcoming catalysts include ESMO presentations and readouts from ongoing studies, particularly in the TIGIT landscape [30] Additional Important Content - The partnership with Gilead includes a deal structure worth up to $850 million, with Compugen leading the Phase I study for GS0321 [24][25] - The mechanism of action for GS0321 involves blocking IL-10 binding protein to unleash the activity of IL-10 in the tumor environment [27][28] - The company is optimistic about the potential of COM701 and its ability to prolong the time from platinum-sensitive status to relapse in ovarian cancer patients [12][30]

Core Insights - iTeos Therapeutics and GSK have decided to terminate the belrestotug development program due to the failure to meet established criteria for clinically meaningful improvements in progression-free survival in the GALAXIES Lung-201 trial [1][3] - The GALAXIES Lung-201 trial showed clinically meaningful improvements in the primary endpoint of objective response rate (ORR), but did not meet criteria for the secondary endpoint of progression-free survival [2][3] - iTeos is initiating a targeted review of strategic alternatives to maximize shareholder value following the termination of the belrestotug program [3][4] Company Overview - iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics [5] - The company is headquartered in Watertown, MA, with a research center in Gosselies, Belgium [5] Product Information - Belrestotug is a monoclonal antibody targeting TIGIT, designed to enhance the antitumor response through immune modulation [6]